Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy

Exclusion Criteria

• •Patients who previously underwent H. pylori eradication therapy
• •Malignant gastric ulcer
• •Linear ulcer
• •Patients with history of upper GI tract resection or vagotomy
• •Patients with continuous NSAIDs use within 4 weeks prior to study initiation
• •Patients with ulcer complications including perforation or pyloric stenosis
• •Gastric ulcer prone to bleeding (e.g. exposed blood vessels at ulcer base)
• •Patients with infectious mononucleosis
• •Patients with known hypersensitivity to penicillin, clarithromycin, omeprazole, amoxicillin or rebamipide
• •Patients on medications such as terfenadine or pimozide which are contraindicated with clarithromycin usage
• •Pregnant or possibly pregnant women, lactating women, or those with a plan to conceive during this study
• •Blood test results of Hb ≤ 8.0 g/dl, platelet ≤50,000 /㎕, total WBC ≤ 4000/㎕ or ≥ 10,000/㎕, and with serum test results showing the levels of AST, ALT, ALP, LDH, BUN, and creatinine exceeding twice the normal range of respective institution.